ROCK2 Inhibitor Optimization Data for Pulmonary Fibrosis

A dataset from a 2026 figshare upload detailing the optimization of Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitors for pulmonary fibrosis therapy. The data likely contains physicochemical and biological evaluation results for compounds developed via molecular planarity disruption strategies. It was authored by Zhi Cao.

Use Cases

• Evaluate compound potency based on IC50 values for ROCK2 inhibition.
• Assess drug-like properties based on kinetic solubility and metabolic stability data.
• Analyze kinase selectivity profiles to identify potential off-target effects.
• Study antifibrotic efficacy based on TGF-β1-induced fibroblast activation and migration suppression.
• Validate design strategies linking molecular planarity disruption to improved physicochemical properties.

Strengths

• Includes specific potency metrics for the optimal compound (IC50 = 0.0081 μM).
• Provides concrete physicochemical data, such as kinetic solubility (77 μg/mL in water) and metabolic stability (t1/2 = 5.0 h for p.o).
• Describes in vivo efficacy results from a bleomycin-induced pulmonary fibrosis model.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is 486.6 KB, indicating a limited scope of data.

Provenance

Source

figshare

Collection Method

Likely generated from experimental research in medicinal chemistry.

Freshness

Last updated 2026-05-25 13:05:51; freshness should be verified.